IDXX

SEC source: 0000874716-24-000102 · wk-form4_1715209318.xml · derivative · entry 8

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 82 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

SEC source: 0000874716-24-000102 · wk-form4_1715209318.xml · derivative · entry 7

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 257 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

SEC source: 0000874716-24-000102 · wk-form4_1715209318.xml · derivative · entry 6

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84

Underlying: Common Stock · 84 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

F2 · shares: Additional grant made as Independent Non-Executive Board Chair.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000102 · wk-form4_1715209318.xml · derivative · entry 5

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262

Underlying: Common Stock · 262 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000102 · wk-form4_1715209318.xml · derivative · entry 4

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195

Underlying: Common Stock · 195 shares

Expires 2034-05-05

F2 · shares: Additional grant made as Independent Non-Executive Board Chair.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000102 · wk-form4_1715209318.xml · derivative · entry 3

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 609

Underlying: Common Stock · 609 shares

Expires 2034-05-05

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000102 · wk-form4_1715209318.xml · nonDerivative · entry 2

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,883

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000102 · wk-form4_1715209318.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,801

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000101 · wk-form4_1715209304.xml · derivative · entry 2

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262

Underlying: Common Stock · 262 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000101 · wk-form4_1715209304.xml · derivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 609

Underlying: Common Stock · 609 shares

Expires 2034-05-05

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000100 · wk-form4_1715209288.xml · derivative · entry 4

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 257 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

SEC source: 0000874716-24-000100 · wk-form4_1715209288.xml · derivative · entry 3

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262

Underlying: Common Stock · 262 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000100 · wk-form4_1715209288.xml · derivative · entry 2

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 609

Underlying: Common Stock · 609 shares

Expires 2034-05-05

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000100 · wk-form4_1715209288.xml · nonDerivative · entry 1

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000099 · wk-form4_1715209255.xml · derivative · entry 4

COLLINS Asha · CIK 0001832272 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 257 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

SEC source: 0000874716-24-000099 · wk-form4_1715209255.xml · derivative · entry 3

COLLINS Asha · CIK 0001832272 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262

Underlying: Common Stock · 262 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event iss earlier.

F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event iss earlier.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event iss earlier.

SEC source: 0000874716-24-000099 · wk-form4_1715209255.xml · derivative · entry 2

COLLINS Asha · CIK 0001832272 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 609

Underlying: Common Stock · 609 shares

Expires 2034-05-05

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000099 · wk-form4_1715209255.xml · nonDerivative · entry 1

COLLINS Asha · CIK 0001832272 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000098 · wk-form4_1715209240.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 863

Underlying: Common Stock · 262 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

SEC source: 0000874716-24-000098 · wk-form4_1715209240.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 609

Underlying: Common Stock · 609 shares

Expires 2034-05-05

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000097 · wk-form4_1715209217.xml · derivative · entry 4

Britt Irene Chang · CIK 0001502314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 208 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

SEC source: 0000874716-24-000097 · wk-form4_1715209217.xml · derivative · entry 3

Britt Irene Chang · CIK 0001502314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262

Underlying: Common Stock · 262 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

SEC source: 0000874716-24-000097 · wk-form4_1715209217.xml · derivative · entry 2

Britt Irene Chang · CIK 0001502314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 609

Underlying: Common Stock · 609 shares

Expires 2034-05-05

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000097 · wk-form4_1715209217.xml · nonDerivative · entry 1

Britt Irene Chang · CIK 0001502314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000096 · wk-form4_1715209202.xml · derivative · entry 6

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 257 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

SEC source: 0000874716-24-000096 · wk-form4_1715209202.xml · derivative · entry 5

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262

Underlying: Common Stock · 262 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000096 · wk-form4_1715209202.xml · derivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 609

Underlying: Common Stock · 609 shares

Expires 2034-05-05

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0000874716-24-000096 · wk-form4_1715209202.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 265,651

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · derivative · entry 11

POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,363

Underlying: Common Stock · 4,640 shares

Expires 2031-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Grant of option to buy 6,003 shares of Issuer common stock that vest in four annual installments beginning February 14, 2022.

SEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · derivative · entry 10

POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,226 shares

Expires 2030-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Grant of option to buy 8,906 shares of Issuer common stock that vest in four annual installments beginning February 14, 2021.

SEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · derivative · entry 9

POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 483 shares

Expires 2029-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2024.

SEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · derivative · entry 8

POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 755 shares

Expires 2029-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Grant of option to buy 5,711 shares of Issuer common stock that vest in five annual installments beginning February 14, 2020.

SEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 7

POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,711.2345

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $559.51 to a high of $559.74 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 6

POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,391.2345

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $558.45 to a high of $559.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 5

POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,681.2345

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $557.33 to a high of $558.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 4

POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,815.2345

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 3

POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,175.2345

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 2

POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,949.2345

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 1

POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,466.2345

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000064 · wk-form4_1709848802.xml · derivative · entry 4

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,404 shares

Expires 2029-05-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on May 6, 2020.

SEC source: 0000874716-24-000064 · wk-form4_1709848802.xml · nonDerivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,216

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $562.9801 to a high of $563.2160 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0000874716-24-000064 · wk-form4_1709848802.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,620

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000061 · wk-form4_1709590727.xml · nonDerivative · entry 1

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,496.5926

SEC source: 0000874716-24-000058 · wk-form4_1708639260.xml · derivative · entry 2

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 483 shares

Expires 2029-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested on February 14, 2024.

SEC source: 0000874716-24-000058 · wk-form4_1708639260.xml · nonDerivative · entry 1

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,046.5926

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000048 · wk-form4_1708466445.xml · derivative · entry 2

Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 483 shares

Expires 2029-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested on February 14, 2024.

SEC source: 0000874716-24-000048 · wk-form4_1708466445.xml · nonDerivative · entry 1

Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,594.9449

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000047 · wk-form4_1708466405.xml · derivative · entry 3

MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 483 shares

Expires 2029-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested on February 14, 2024.

SEC source: 0000874716-24-000047 · wk-form4_1708466405.xml · nonDerivative · entry 1

MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,834.5926

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-24-000044 · wk-form4_1708124315.xml · derivative · entry 14

Underberg Sharon E. · CIK 0001630353 · EVP, GC & Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 528

Underlying: Common Stock · 176 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024.

F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024.

F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024.